Verapamil reversal of clinical doxorubicin resistance in human cancer. A Wilshire Oncology Medical Group pilot phase I-II study.

@article{Presant1986VerapamilRO,
  title={Verapamil reversal of clinical doxorubicin resistance in human cancer. A Wilshire Oncology Medical Group pilot phase I-II study.},
  author={Cary A. Presant and Phil Kennedy and Charles Wiseman and Kaushik Gala and A Bouzaglou and M R Wyres and V L Naessig},
  journal={American journal of clinical oncology},
  year={1986},
  volume={9 4},
  pages={355-7}
}
A pilot study of the use of verapamil and adriamycin in patients with advanced malignancy was conducted to determine if the two drugs could be safely combined and to explore whether antitumor responses were frequent. The dosage of adriamycin was 50 mg/M2 every 3 weeks. Eight doses of verapamil were given orally every 6 hours, with adriamycin being… CONTINUE READING